Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05452226 · ClinicalTrials.gov registry record · NA

Neuromuscular Electrical Stimulation in COPD/Community Acquired Pneumonia

A NA study of Community-acquired Pneumonia and COPD Exacerbation Acute, sponsored by University of Vermont.

Recruiting
Registry status
NA
Development phase
8
Enrollment target
1
Study location

NCT05452226 is a NA study of Community-acquired Pneumonia and COPD Exacerbation Acute that is actively recruiting participants, run by University of Vermont. The registered enrollment target is 8 participants, below the 109,120-participant average among 9 other Community-acquired Pneumonia trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05452226, a NA study of Community-acquired Pneumonia and COPD Exacerbation Acute, is actively recruiting participants, sponsored by University of Vermont.

RECRUITING
Registry status
NA
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

In older adults hospitalized for acute medical conditions, immobility, clinical treatments, and the illness itself contribute to physical deconditioning and delirium, hospital-acquired impairments that increase risk for long-term physical and mental disability, other morbidities, and death. In patients with acute respiratory failure, hospital-acquired functional impairments persist long after hospitalization, due to limited use to rehabilitative interventions in the inpatient or post-acute settings. Exercise and early mobilization interventions are safe and improve physical and cognitive impairments, but there are critical barriers to their widespread implementation in acute care and home settings, including mobility limitations, reduced cardiopulmonary reserve, limited staff, and costs. Thus, there is an unmet need to develop interventions that can be utilized in both the inpatient and home environments to improve functional recovery in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and community-acquired pneumonia (CAP). This study addresses this clinical need and these barriers and will provide important feasibility and acceptability data regarding the utility of neuromuscular electrical stimulation (NMES) administered to lower extremity musculature across inpatient and post-discharge settings to improve functional and cognitive recovery in older adults hospitalized for AECOPD/CAP. Initial NMES sessions will begin during participants' stay at UVM Medical Center and will continue at home after hospital discharge. Study participants will be issued a portable NMES device to take home and instructed on its use. They will receive guidance and oversight on the use of the NMES device and will be asked to perform NMES treatments 6 days per week for 60 minutes per day for 6 weeks. Data will be collected via activity monitor, participant questionnaires and clinical assessments including strength testing and 6-minute-walk-test.

Interventions

  • DEVICE neuromuscular electrical stimulation (NMES)

Study Locations (1)

Vermont

  • University of Vermont - Burlington

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2022-07-12
Est. Completion 2025-12-30
Phase NA

Sponsor

University of Vermont

162 total trials

What the Registry Record Tells You About NCT05452226

The ClinicalTrials.gov registry entry for NCT05452226 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109,120-participant average among 9 other Community-acquired Pneumonia trials with a reported enrollment target (100% lower). The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Community-acquired Pneumonia appearing as the primary indexed condition, and to 1 intervention - of which neuromuscular electrical stimulation (NMES) is the first listed.

NCT05452226 reports 1 study location spanning 1 distinct geographic area - top geographies include Vermont.

Frequently Asked Questions

What is clinical trial NCT05452226 about?

NCT05452226 is a clinical study titled "Neuromuscular Electrical Stimulation in COPD/Community Acquired Pneumonia". In older adults hospitalized for acute medical conditions, immobility, clinical treatments, and the illness itself contribute to physical deconditioning and delirium, hospital-acquired impairments that increase risk for long-term physical and mental disability, other morbidities, and death. In patie...

What is the current status of trial NCT05452226?

This trial is currently recruiting. It is a NA study. The enrollment target is 8 participants. The study started on 2022-07-12. Estimated completion is 2025-12-30.

What conditions does trial NCT05452226 study?

This clinical trial studies the following conditions: Community-acquired Pneumonia, COPD Exacerbation Acute.

What interventions are being tested in trial NCT05452226?

The interventions under investigation include: neuromuscular electrical stimulation (NMES) (DEVICE).

Who is sponsoring clinical trial NCT05452226?

This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05452226 being conducted?

This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Community-acquired Pneumonia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.